ADJUVANT THERAPY IN BREAST CANCER

Allred, 1993, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer, J Natl Cancer Inst, 85, 200, 10.1093/jnci/85.3.200 Allred, 1992, HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma, J Clin Oncol, 10, 599, 10.1200/JCO.1992.10.4.599 Blomqvist, 1992, The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer: Long-term follow-up results of a randomized trial, Br J Cancer, 66, 1171, 10.1038/bjc.1992.430 Bonadonna, 1992, Evolving concepts in the systemic adjuvant treatment of breast cancer, Cancer Res, 52, 2127 Bonadonna, 1993, Risk of acute leukemia and other malignancies following CMF-based adjuvant chemotherapy for breast cancer, Proc ASCO, 12, 61 Campora, 1992, Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF, Anticancer Res, 12, 1555 Carpenter, 1991, Prospective, randomized comparison of cyclophosphamide, doxorubicin (Adriamcyin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for breast cancer with positive axillary nodes, Proc ASCO, 10, 45 Carter, 1989, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 63, 181, 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H Clark, 1992, Prognostic significance of S-phase fraction in good-risk, node negative breast cancer patients, J Clin Oncol, 10, 428, 10.1200/JCO.1992.10.3.428 Cobleigh, 1994, Estrogen replacement therapy in breast cancer survivors, JAMA, 272, 540, 10.1001/jama.1994.03520070060039 1985, Consensus conference. Adjuvant chemotherapy for breast cancer, JAMA, 254, 3461, 10.1001/jama.1985.03360240073038 Cummings, 1993, Adjuvant tamoxifen vs. placebo in elderly women with node positive breast cancer: Long-term follow-up and causes of death, J Clin Oncol, 11, 29, 10.1200/JCO.1993.11.1.29 Curtis, 1992, Risk of leukemia after chemotherapy and radiation treatment for breast cancer, N Engl J Med, 326, 1745, 10.1056/NEJM199206253262605 Dimitrov, 1994, Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22, Proc Am Soc Clin Oncol 1992, Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet, 339, 1 Elston, 1987, Grading of invasive carcinoma of the breast Fentiman, 1992, Tamoxifen protects against steroid-induced bone loss, Eur J Cancer, 28, 684, 10.1016/S0959-8049(05)80125-X Fisher, 1990, J Clin Oncol, 8, 1483, 10.1200/JCO.1990.8.9.1483 Fisher, 1989, A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative tumors, N Engl J Med, 320, 473, 10.1056/NEJM198902233200801 Fisher, 1992, Prognostic factors in NSABP studies of women with node-negative breast cancer, J Natl Cancer Inst, 11, 151 Fisher, 1992, Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer, Semin Oncol, 19, 263 Foekens, 1993, Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariety analysis, J Clin Oncol, 11, 899, 10.1200/JCO.1993.11.5.899 Gelber, 1993, Adjuvant therapy for breast cancer: Understanding the overview, J Clin Oncol, 11, 580, 10.1200/JCO.1993.11.3.580 Gianni, 1992, Growth factor-supported high dose sequential adjuvant chemotherapy in breast cancer with 10 positive nodes, Proc ASCO, 11, 60 Hryniuk, 1988, The importance of dose intensity of the outcome of chemotherapy, Important Adv Oncol, 121 Isola, 1993, Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer, J Clin Oncol, 11, 899, 10.1200/JCO.1993.11.1.36 Kaufmann, 1993, Adjuvant randomized trials of doxorubicin/cyclophosphamide vs. doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy vs. Tamoxifen in women with node-positive breast cancer, J Clin Oncol, 11, 454, 10.1200/JCO.1993.11.3.454 Kiricuta, 1992, A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma, Cancer, 69, 2496, 10.1002/1097-0142(19920515)69:10<2496::AID-CNCR2820691018>3.0.CO;2-T Levine, 1990, A randomized trial comparing 12 weeks with 36 weeks of adjuvant chemotherapy in stage II of breast cancer, J Clin Oncol, 8, 1217, 10.1200/JCO.1990.8.7.1217 Love, 1992, Tamoxifen in axillary node-negative breast cancer: Multisystem benefits and risks, Cancer Invest, 10, 587, 10.3109/07357909209024821 Mansour, 1992, The value of prognostic factors in selecting node-negative breast cancer patients for adjuvant therapy, J Surg Oncol, 49, 73, 10.1002/jso.2930490202 Mauriac, 1992, Randomized trial of adjuvant chemotherapy for operable breast cancer comparing I.V. CMF to an epirubicin-containing regimen, Ann Oncol, 3, 439, 10.1093/oxfordjournals.annonc.a058231 McGuire, 1992, Prognostic factors and treatment decisions in axillary node-negative breast cancer, N Engl J Med, 326, 1756, 10.1056/NEJM199206253262607 Moliterni, 1991, Cyclophosphamide, methotrexate, and fluoroucil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes, J Clin Oncol, 9, 1124, 10.1200/JCO.1991.9.7.1124 Muss, 1994, C-erbB-2 expression and S-phase activity, predict response to adjuvant therapy in women with node positive early breast cancer: A comparison study of the cancer and acute leukemia group B (CALGB), N Engl J Med, 330, 1260, 10.1056/NEJM199405053301802 National Institutes of Health Consensus Development Panel, 1992, Consensus statement: Treatment of early-stage breast cancer, J Natl Cancer Inst, 11, 1 Neville, 1992, Factors predicting treatment responsiveness and prognosis in node-negative breast cancer, J Clin Oncol, 10, 696, 10.1200/JCO.1992.10.5.696 1991, NIH Consensus Conference: Treatment of early stage breast cancer, JAMA, 265, 391, 10.1001/jama.1991.03460030097037 Peters, 1993, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer, J Clin Oncol, 11, 1132, 10.1200/JCO.1993.11.6.1132 Rakowsky, 1992, Prognostic Factor in Node-Positive Operable Breast Cancer Patients Receiving Adjuvant Chemotherapy, Breast Cancer Research and Treatment, 21, 121, 10.1007/BF01836958 Rosen, 1989, A Long-term follow-up study of survival in stage I (T1NOMO) and stage II (T1N1MO) breast carcinoma, J Clin Oncol, 7, 355, 10.1200/JCO.1989.7.3.355 Shapiro, 1993, Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes, J Natl Cancer Inst, 85, 812, 10.1093/jnci/85.10.812 Tormey, 1992, Adjuvant therapy with doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients, J Clin Oncol, 10, 1848, 10.1200/JCO.1992.10.12.1848 Valagussa, 1993, Cardiac effects of adjuvant chemotherapy in operable breast cancer, Proc ASCO, 12, 61 Velez, 1992, Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: A South-Eastern Cancer Study Group trial, Eur J Cancer, 28A, 1833, 10.1016/0959-8049(92)90015-T Weidner, 1992, Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma, J Natl Cancer Inst, 84, 1875, 10.1093/jnci/84.24.1875 Wolf, 1992, Gynecologic complications associated with long term adjuvant tamoxifen therapy in breast cancer, Gynecol Oncol, 45, 118, 10.1016/0090-8258(92)90273-L Wood, 1994, Dose and dose intensity trial of adjuvant chemotherapy for stage II, node positive breast carcinoma: Initial results of CALGB 8541, N Engl J Med, 1253, 10.1056/NEJM199405053301801